Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ: PRTA )

14.07 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Earnings Preview For Prothena Corp
Via Benzinga
Prothena to Report Third Quarter 2023 Financial Results on November 2
From Prothena Corporation plc
Via Business Wire
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment
Both companies are working on under-the-skin injections for Alzheimer's treatment. 
Via Investor's Business Daily
Expert Ratings for Prothena Corp
Via Benzinga
Expert Ratings for Prothena Corp
Via Benzinga
JMP Securities Maintains Outperform Rating for Prothena Corp: Here's What You Need To Know
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Prothena Corp's Earnings Outlook
Via Benzinga
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
Lululemon, PCTEL, Consolidated Communications, Other Stocks Jumping Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Monday. Here are some stocks recording big gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Ratings for Prothena Corp
Via Benzinga
8 Analysts Have This to Say About Prothena Corp
Via Benzinga
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
Looking Into Prothena Corp's Return On Capital Employed
Via Benzinga
Recap: Prothena Corp Q1 Earnings
Via Benzinga
Prothena Corp Earnings Preview
Via Benzinga
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Second Quarter 2023 Financial Results on August 3
From Prothena Corporation plc
Via Business Wire
Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)
From Prothena Corporation plc
Via Business Wire
Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)
From Prothena Corporation plc
Via Business Wire
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
From Prothena Corporation plc
Via Business Wire
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab
From Prothena Corporation plc
Via Business Wire
Prothena to Participate in Jefferies 2023 Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
From Prothena Corporation plc
Via Business Wire
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Another Sucess In Alzheimer’s Disease
Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments? 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.